The stock of Radius Health Inc (NASDAQ:RDUS) is a huge mover today! About 170,615 shares traded hands. Radius Health Inc (NASDAQ:RDUS) has risen 30.01% since April 21, 2016 and is uptrending. It has outperformed by 24.68% the S&P500.
The move comes after 8 months positive chart setup for the $2.14 billion company. It was reported on Nov, 23 by Barchart.com. We have $55.63 PT which if reached, will make NASDAQ:RDUS worth $171.20M more.
Analysts await Radius Health Inc (NASDAQ:RDUS) to report earnings on February, 23. They expect $-1.13 earnings per share, down 46.75% or $0.36 from last year’s $-0.77 per share. After $-1.07 actual earnings per share reported by Radius Health Inc for the previous quarter, Wall Street now forecasts 5.61% negative EPS growth.
Radius Health Inc (NASDAQ:RDUS) Ratings Coverage
Out of 9 analysts covering Radius Health (NASDAQ:RDUS), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. Radius Health has been the topic of 13 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock has “Neutral” rating given by Goldman Sachs on Wednesday, March 30. The stock of Radius Health Inc (NASDAQ:RDUS) earned “Buy” rating by H.C. Wainwright on Monday, May 23. The stock of Radius Health Inc (NASDAQ:RDUS) has “Overweight” rating given on Friday, October 2 by JP Morgan. The firm has “Hold” rating by Jefferies given on Wednesday, February 24. The company was initiated on Friday, August 14 by Deutsche Bank. On Wednesday, September 21 the stock rating was maintained by H.C. Wainwright with “Buy”. Canaccord Genuity maintained the stock with “Buy” rating in Thursday, September 24 report. The firm has “Outperform” rating given on Friday, May 6 by Cowen & Co.
According to Zacks Investment Research, “Radius Health Inc. is a science-driven biopharmaceutical company. It is focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the prevention of fractures in post-menopausal women at risk of fracture from osteoporosis. Radius Health Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.44 in Q2 2016. Its up 0.12, from 1.32 in 2016Q1. The ratio is positive, as 20 funds sold all Radius Health Inc shares owned while 33 reduced positions. 22 funds bought stakes while 48 increased positions. They now own 42.68 million shares or 5.94% more from 40.29 million shares in 2016Q1.
Next Fincl Group has 150 shares for 0% of their US portfolio. Cowen Grp Incorporated last reported 0.02% of its portfolio in the stock. Teacher Retirement Sys Of Texas, a Texas-based fund reported 4,169 shares. Vanguard Grp accumulated 0.01% or 2.62 million shares. Prudential Financial Inc last reported 0% of its portfolio in the stock. The New York-based Cornerstone Ltd Liability Company has invested 0% in Radius Health Inc (NASDAQ:RDUS). The Maryland-based Profund Advsr Ltd Com has invested 0.03% in Radius Health Inc (NASDAQ:RDUS). Blackrock Institutional Trust Co Na accumulated 792,644 shares or 0% of the stock. Mpm Asset Limited Liability last reported 69.51% of its portfolio in the stock. Stifel Finance accumulated 11,376 shares or 0% of the stock. Nuveen Asset Mngmt Ltd Llc holds 0.01% or 35,145 shares in its portfolio. Centurylink Investment Mgmt holds 6,202 shares or 0.08% of its portfolio. Neuberger Berman Gru holds 0% of its portfolio in Radius Health Inc (NASDAQ:RDUS) for 12,500 shares. Quantbot Technologies Limited Partnership, a New York-based fund reported 633 shares. Creative Planning accumulated 0% or 2,600 shares.
Another recent and important Radius Health Inc (NASDAQ:RDUS) news was published by Zacks.com which published an article titled: “Radius Health (RDUS): Will It Disappoint in Q3 Earnings?” on November 01, 2016.
RDUS Company Profile
Radius Health, Inc. is a biopharmaceutical firm focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. The Company’s preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.